NVCTNuvectis Pharma, Inc.
$20.13+229% 1Y
$20.13
$5.6552 weeks$28.52
What is the market doing?
Mixed
1 neutral, 2 without dataRangebound. That is the only one of 3 checks this filer's data supports, so take it as a single data point rather than a settled answer.
TrendRangeboundderived · Oct 8, 2026
Choppy, but holding above its 200-day average. Price is +47% vs its 200-day average.
Where this answer is blind. Insider selling is often routine (taxes, diversification); only cluster buying is a strong tell.
How NVCT is trading
Nuvectis Pharma, Inc. is +229% over the past year while the S&P 500 is +18%: 211 points ahead of the market.
+229%
1-year return · S&P 500 +18%
- vs 200-day average
- +47%
vs 200-day average · a clear uptrend
- RSI (14)
- 41
RSI (14) · neutral
- Below its 52-week high
- 29%
Below its 52-week high
Details›
- Last close2026-10-08
- $20.13
- 1 monthS&P 500 +1.6%
- −11%
- 1 yearS&P 500 +18%
- +229%
- vs 50-day average$21.79
- −7.6%
- 52-week high
- $28.52
- 52-week low
- $5.65
- Annualised volatility
- 90%
| Year | Return |
|---|---|
| 2026 (year to date) | +167% |
| 2025 | +40% |
| 2024 | −35% |
| 2023 | +11% |
| Month | Years | Positive | Average |
|---|---|---|---|
| Jan | 4 | 3 of 4 | +13% |
| Feb | 4 | 3 of 4 | +15% |
| Mar | 5 | 3 of 5 | +7.8% |
| Apr | 5 | 4 of 5 | +5.6% |
| May | 5 | 4 of 5 | +19% |
| Jun | 5 | 1 of 5 | +5.2% |
| Jul | 5 | 2 of 5 | −4.4% |
| Aug | 5 | 3 of 5 | +0.63% |
| Sep | 5 | 0 of 5 | −9.4% |
| Oct | 5 | 2 of 5 | −2.0% |
| Nov | 4 | 1 of 4 | −9.0% |
| Dec | 4 | 3 of 4 | +7.1% |
End-of-day closes from IEX; the S&P 500 comparison uses SPY over the same window. Prices are a reference point, not a basis for trading decisions.